Blog · Weight Loss
You were losing steadily, and now the scale won’t budge. A semaglutide plateau can feel like the medicine quit, but it’s one of the most predictable parts of treatment. Below, Dr. Melanie Espinet explains what the research says about why weight loss stalls on GLP-1 medicine, including tirzepatide, how to tell a true plateau from normal ups and downs, and what a physician can adjust. If you’re earlier in treatment, the semaglutide weight loss timeline shows when slowing down is expected.
A plateau is the point where weight loss slows to a near stop, even though you are still taking your medicine and following your plan. Researchers describe it as the body moving from losing weight to holding steady. There is no single agreed definition, which is part of why it confuses people.
The trials show it clearly. In the STEP 1 trial of semaglutide 2.4 mg, the published weight curve shows average weight falling steadily in the first months, then more slowly, until it reached its lowest point around week 60 of the 68-week trial. For tirzepatide, a published analysis of the SURMOUNT-1 trial found that nearly 9 in 10 people who responded had reached a plateau by week 72. A plateau isn’t a sign something went wrong. It is what weight loss on these medicines usually looks like over time.
Your body defends its weight. As you lose, two things change at once:
The review’s authors think the appetite side likely matters more than the slower metabolism. Over time, those changes catch up with the calories you cut, and weight levels off. The shift can also be quiet: the brain regulates appetite below conscious awareness, so portions can creep up slowly without you noticing.
Semaglutide and tirzepatide lower calorie intake, likely by acting on appetite, and in their trials they led to far more weight loss than diet and activity counseling alone. But they don’t switch off the body’s defenses. None of this is a willpower problem. It is physiology, and it is why weight management is a long-term plan rather than a sprint.
Before you change anything, make sure you are looking at a true plateau. Researchers note that a change of 1 to 2 percent in body weight is within normal fluctuation, so a flat week means little. Here is how to read what you see:
| What you see | What it may mean |
|---|---|
| The scale is flat for a week or two | Usually normal fluctuation. Look at your trend over at least a month. |
| You are still in the dose-increase months | Too early to judge. In the trials, people kept losing well after the dose increases ended. |
| Little change over about 12 weeks, after months of steady loss | Likely a true plateau. Time for a review with your physician. |
| Less than 5 percent lost after 12 weeks on the full dose | The NIH says your doctor will probably advise stopping that medicine, and may change the plan. |
| Weight is rising steadily | Not a plateau. Tell your physician soon, so the cause can be checked. |
A tape measure around your waist, how your clothes fit, and your energy can show progress the scale misses. Keep notes, so your next check-in starts from facts.
When the scale stalls, it helps to look beyond the medicine itself. Here are common reasons, several of them from the NIH’s list of factors that can contribute to weight gain:
Questions about drinking while you’re on treatment? See our guide to semaglutide and alcohol.
There is no single fix, and pushing harder isn’t always the right answer. When a weight management medicine hasn’t brought enough weight loss, the NIH says a doctor may change the treatment plan, try a different medicine, suggest a different eating or activity program, or change other medicines that might be causing weight gain. Here is how those levers look in practice.
Both prescribing labels say the maintenance dose should be chosen based on how you respond and how well you tolerate it. That can mean a step up, staying put, or stepping down if side effects are wearing you down. In SURMOUNT-1, higher tirzepatide doses led to more weight loss on average and a later plateau. A higher dose is never automatic: Dr. Espinet weighs your progress, side effects and goals first.
When appetite is low, meals can drift toward whatever is easy. The NIH-led review notes that protein helps body composition during weight loss, gives resting metabolism a small boost, and is more filling than carbohydrate or fat. Building each meal around a protein is a practical first step. See what to eat on semaglutide for a full plan.
In both medicines’ main trials, participants were counseled toward at least 150 minutes of activity a week, and the review lists more physical activity among the habits linked with keeping weight off. If you’ve slowed down as the weeks went on, rebuilding a routine is a fair place to start. Keeping muscle matters too, and our guide to muscle loss on GLP-1 medicine explains why.
If a medicine you take may contribute to weight gain, raise it with your physician, and ask the doctor who prescribed it whether there is an alternative. Never stop a prescribed medicine on your own. Sleep and long-term stress are worth raising at your check-in too.
If semaglutide has stopped helping and your goals call for more, a different medicine may be worth discussing. Our guide to switching from semaglutide to tirzepatide covers how that works. Sometimes the right call is to hold. The NIH notes that losing 5 to 10 percent of your starting weight may improve blood sugar, blood pressure and triglycerides. If you have lost enough to improve your health without serious side effects, your doctor may advise staying on the medicine indefinitely.
Not really. The same physiology applies, and the SURMOUNT-1 weight curve has the same shape. In the published analysis of SURMOUNT-1, among people who kept taking tirzepatide and lost at least 5 percent, the typical (median) time to a plateau was about 24 weeks for people who started in the overweight range and about 36 weeks for those who started with a BMI of 35 or higher. Higher doses, younger age and female sex were linked with reaching a plateau later, and people who plateaued later had usually lost more by then.
The authors defined a plateau loosely, as less than 5 percent change over a 12-week stretch, and noted that no agreed definition exists. So treat these numbers as a rough guide. For tirzepatide care and pricing, see tirzepatide weight loss in Lutz.
Not without talking to your physician. The SURMOUNT analysis points out that a plateau is often mistaken for the end of the medicine’s benefit. In the SURMOUNT-4 trial, participants first took tirzepatide for 36 weeks, then were randomly assigned to keep taking it or switch to placebo. Between week 36 and week 88, people who stayed on it lost another 5.5 percent of their week-36 weight on average, while people switched to placebo gained 14.0 percent.
The NIH says you will probably regain some weight after you stop a weight management medicine. A plateau can be the start of the maintenance phase, when the medicine helps you hold your new weight. See stopping semaglutide for what to expect if you do stop.
Check-ins are built into every MeliOra GLP-1 plan, and a plateau is exactly what they are for. Dr. Melanie Espinet, a board-certified family physician, reviews your progress, side effects and habits with you, then decides with you whether to adjust your dose, change course, or focus on holding your new weight. Dose adjustments and check-ins are included in your monthly price, along with physician visits, lab work, and the medication and supplies. Semaglutide starts at $150/month, with higher dosing at $240/month, and tirzepatide runs $230/month to $320/month. Dr. Espinet will walk you through what any change means for your plan at your visit.
Visits happen at your home or office across Tampa Bay with no travel fee, at our Lutz office for select appointments, or by telehealth anywhere in Florida. If you started GLP-1 treatment somewhere else and have stalled, bring your dose history to a semaglutide consultation in Lutz. No physician can promise to break every plateau, but you won’t be left guessing alone.
Yes. A plateau is an expected stage of treatment, and most people reach one. In the STEP 1 trial, average weight on semaglutide 2.4 mg reached its lowest point around week 60 of 68, and in an analysis of SURMOUNT-1, nearly 9 in 10 people who responded to tirzepatide had plateaued by week 72.
There is no set length. A true plateau is your body’s new balance point, so it usually lasts until something in the plan changes, and it can become the start of long-term maintenance. Your physician can help you decide whether to aim lower or hold steady.
Often it is the expected slowdown as your body adapts to a lower weight. Other causes include being early in the dose increases, missed doses, short sleep, long-term stress, hormone conditions such as hypothyroidism, and other medicines that can cause weight gain. Your physician can sort out which applies to you.
Not automatically. The prescribing labels say the maintenance dose should be based on how you respond and how well you tolerate it, so a step up, staying put, or a step down can each be right. Your physician weighs your progress, side effects and goals before changing anything.
Check the trend first, then bring it to your physician. Look at at least a month of weigh-ins, since a 1 to 2 percent swing is normal. If you have been flat for about 12 weeks, your physician can review your dose, eating, activity, sleep and other medicines with you.
Talk with your physician if you have not lost at least 5 percent of your starting weight after 12 weeks on the full dose. The NIH says a doctor will probably advise stopping a medicine in that case, and may suggest a different medicine or another approach.
Yes. In an analysis of SURMOUNT-1, the typical time to a plateau on tirzepatide was about 24 to 36 weeks, depending on starting BMI, and higher doses, younger age and female sex were linked with a later plateau. The body’s response to weight loss works the same way on either medicine.
You probably will regain some. The NIH says you will probably regain some weight after you stop a weight management medicine, and in the SURMOUNT-4 trial, people switched from tirzepatide to placebo regained weight while those who stayed on it kept losing. Talk with your physician before you stop.
Serving Lutz, Wesley Chapel, Land O'Lakes, Carrollwood, New Tampa & greater Tampa Bay.
Book Your Consultation
Free download · 15 pages
Typical units and cost by area, Botox brands Jeuveau vs. Xeomin, aftercare, a results timeline and a planner you can fill in. Free, and yours to keep.
Get the free guide
